Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.32 |
| ▸ | VEGFA | P15692 | 2/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2342720 | 0.97 | CYP3A4 (0.51) | CYP3A4KCNH2CYP2C9CYP2C19SLC22A12 | |
| SCHEMBL5915079 | 0.91 | CYP3A4 (0.55) | CYP3A4KCNH2CYP2C9CYP2C19 | |
| SCHEMBL2345051 | 0.88 | CYP3A4 (0.53) | CYP3A4KCNH2CYP2C9CYP2C19 | |
| SCHEMBL5180307 | 0.87 | CYP3A4 (0.49) | CYP3A4KCNH2CYP2C9CYP2C19 | |
| SCHEMBL1654901 | 0.85 | CYP3A4 (0.55) | CYP3A4KCNH2CYP2C9CYP2C19 | |
| SCHEMBL2347420 | 0.84 | CYP3A4 (0.47) | CYP3A4KCNH2CYP2C9CYP2C19 | |
| SCHEMBL5178143 | 0.82 | CYP3A4 (0.45) | CYP3A4KCNH2CYP2C9CYP2C19EPAS1 | |
| SCHEMBL11903899 | 0.81 | CYP3A4 (0.59) | CYP3A4KCNH2CYP2C9CYP2C19SLC22A12 | |
| SCHEMBL5179004 | 0.80 | CYP3A4 (0.43) | CYP3A4KCNH2CYP2C9CYP2C19EPAS1 | |
| SCHEMBL5322461 | 0.80 | CYP3A4 (0.80) | CYP3A4KCNH2CYP2C9CYP2C19SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773790-B1 | BENZYLTRIAZOLONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2012-08-15 | — | — | EP | disclosed |
| EP-1773790-A1 | BENZYLTRIAZOLONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-18 | — | — | EP | disclosed |
| US-20060025462-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-02-02 | — | — | US | disclosed |
| WO-2006010545-A1 | BENZYLTRIAZOLONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025462-A1 | Heterocyclic antiviral compounds | MAVS, IRF3, ZC3HAV1 | CYP3A4 893/4885KCNH2 2376/4885CYP2C9 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.